Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program

Not Applicable

Completed

• Conditions: Early Inflammatory Arthritis; Chronic Disease

• Registration Number: NCT01054131
• Lead Sponsor: Sunnybrook Health Sciences Centre

Brief Summary

Inflammatory arthritis (IA) is a major cause of long-term disability. Peer support may be a solution to the common problem of delayed treatment. Early peer support may result in improved use of therapy, higher self-efficacy, reduced anxiety, and improved coping in the first two years post-diagnosis. The whole intervention study comprises of two parts: The first part involves the development and testing of a peer mentor training initiative, which is called "Peer to Peer Mentoring: Facilitating Individuals with Early Inflammatory Arthritis to Manage their Arthritis - Peer Mentor Training". The second part, which is the focus of this study, involves the delivery of a one-on-one peer support intervention from a trained peer mentor to an individual newly diagnosed with EIA. The feasibility and acceptability of the program will be determined, as well as the health outcomes following the participation of the program.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2010-01-21
• Study First Submitted QC: 2010-01-21
• Study First Posted: 2010-01-22
• Primary Completion: 2011-09
• Status Verified: 2011-12
• Study Completion: 2011-12
• Last Update Submitted: 2011-12-23
• Last Update Posted: 2011-12-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Have EIA disease duration within 6-52 weeks
2. At least 3 swollen joints, assessed by the treating rheumatologist, OR positive compression test for the metacarpophalangeal joints OR positive compression test for the metatarsophalangeal joints OR at least 30 minutes of morning stiffness
3. Prescription of a DMARD/biologic by the treating rheumatologist
4. Ability to speak and understand English without the aid of a secondary support person; AND
5. Capability to provide informed consent.

Exclusion Criteria

1. IA disease duration less than 6 weeks or greater than 1 year
2. Previous or ongoing DMARD or biologic treatment
3. Inability to speak or read grade 6 English; AND
4. Inability to provide informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
DMARD adherence	0, 3, 6 months

Secondary Outcome Measures

Name	Time	Method
coping efficacy	0, 3 6 months
self-management	0, 3, 6 months
anxiety	0, 3, 6 months
self efficacy	0, 3, 6 months
social support	0, 3, 6 months

Trial Locations

Locations (1)

Sunnybrook Health Sciences Centre; 🇨🇦 Toronto, Ontario, Canada